PEI MELINDA LITHERLAND 4

What Happened

• On April 21, 2026, Bio‑Rad director Melinda Litherland reported derivative conversions and an award. The filing shows 407 shares from a derivative exercise/conversion (code M) were acquired and 407 shares (code M) were disposed, and an award/grant (code A) of 369 restricted stock units (RSUs) was recorded. All transactions show a reported price of $0.00 and $0 total value.
• These transactions represent share issuance on vesting/conversion rather than open‑market purchases or sales. The net disposal of the 407 shares likely reflects a withholding or net settlement related to the vesting/conversion (common when shares are issued for compensation), not a public sale.

Key Details

• Transaction date: 2026-04-21; Form 4 filed: 2026-04-23 (filed timely).
• Transaction codes: M = exercise/conversion of a derivative; A = award/grant (RSU).
• Share counts and prices: 407 shares exercised/converted acquired @ $0.00; 407 shares disposed @ $0.00; 369 RSUs granted @ $0.00.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: F1–F3 state these shares were issued on vesting of RSUs; each RSU equals a contingent right to one Class A share; the RSUs vest 100% on the earlier of the first anniversary of the grant or the next annual meeting.

Context

• RSU awards and conversions are compensation-related and do not necessarily signal a change in insider sentiment like an open‑market buy or sell would. The matching conversion + disposal pattern is commonly used to satisfy tax withholding or net‑settlement obligations when RSUs vest.